Invention Grant
- Patent Title: Osteoclast inhibitors for knee conditions
-
Application No.: US15335381Application Date: 2016-10-26
-
Publication No.: US09694022B2Publication Date: 2017-07-04
- Inventor: Herriot Tabuteau
- Applicant: ANTECIP BIOVENTURES II LLC
- Applicant Address: US NY New York
- Assignee: ANTECIP BIOVENTURES II LLC
- Current Assignee: ANTECIP BIOVENTURES II LLC
- Current Assignee Address: US NY New York
- Agency: K&L Gates LLP
- Agent Brent A. Johnson; Yuefen Zhou
- Main IPC: A61K31/66
- IPC: A61K31/66 ; A61K31/663 ; A61K31/675 ; A61K45/06 ; A61K9/00 ; A61K9/20 ; A61K31/573
Abstract:
Oral dosage forms of osteoclast inhibitors, such as nitrogen-containing bisphosphonates, can be used to treat or alleviate pain or related conditions.
Public/Granted literature
- US20170042914A1 Osteoclast Inhibitors for Knee Conditions Public/Granted day:2017-02-16
Information query
